Sequence: AGYLLGKLLOOLAAAALOOLL
| Experiment Id | EXP001378 |
|---|---|
| Paper | Chitosan enhances gene delivery of oligonucleotide complexes with magnetic nanoparticles–cell-penetr |
| Peptide | PF14 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | SCO (10 µM used in complex preparation) |
| Mixing Ratio | MR 10:1 (CPP:SCO) (paper also discusses MR20 in results figure) |
| Formulation Format | noncovalent CPP–RNA complex with chitosan-modified Fe3O4 magnetic nanoparticles (CTS@MNPs) |
| Formulation Components | CTS@Fe3O4 magnetic nanoparticles (chitosan-modified iron oxide MNPs) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa puLuc 705 |
| Animal Model | |
| Administration Route | |
| Output Type | splice-correction luciferase assay |
| Output Value | >6-fold vs PF14–SCO (reported) |
| Output Units | |
| Output Notes | Presence of CTS@MNPs increased PF14–SCO splice-correction activity by >6-fold vs PF14–SCO alone (in vitro). Confocal microscopy confirmed internalization for PF14–(fluorescent 705 ASO)–CTS@MNPs complexes. |
| Toxicity Notes | WST-1 assay: complexes reported biocompatible / no observed cytotoxicity in HeLa cells. |
| Curation Notes |